The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
Abstract
Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. Previous studies with the selective COX-2 inhibitors, rofecoxib and celecoxib, have shown that they do not alter the progression of AD. We conducted a double-blind study to investigate whether rofecoxib could delay a diagnosis of AD in patients with mild cognitive impairment (MCI), a group with an expected annual AD diagnosis rate of 10-15%. MCI patients > or =65 years were randomized to rofecoxib 25 mg (N=725) or placebo (N=732) daily for up to 4 years. The primary end point was the percentage of patients with a clinical diagnosis of AD. The estimated annual AD diagnosis rate was lower than the anticipated 10-15%: 6.4% in the rofecoxib group vs 4.5% in the placebo group (rofecoxib : placebo hazard ratio=1.46 (95% CI: 1.09, 1.94), p=0.011). Analyses of secondary end points, including measures of cognition (eg the cognitive subscale of the AD Assessment Scale (ADAS-Cog)) and global function (eg the Clinical Dementia Rating (CDR)), did not demonstrate differences between treatment groups. There was also no consistent evidence that rofecoxib differed from placebo in post hoc analyses comparing ADAS-Cog and CDR-sum of boxes scores in overlapping subgroups of patients who had Mini Mental State Exam scores of 24-26 in the present MCI study and in a previous AD treatment study with a similar design. The results from this MCI study did not support the hypothesis that rofecoxib would delay a diagnosis of AD. In conjunction with the lack of effects observed in previous AD studies, the findings suggest that inhibition of COX-2 is not a useful therapeutic approach in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unexpectedly, clinical trials targeting inflammation with NSAIDs have not improved cognition in AD patients [111, 112].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [112]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Arky, R. A. (1994) · Cited by 2,632
Flagged first, then by citations
Research works printed but not linked: 3
- Bresalier RS, Sandler R, Riddell R, Lanas A, Morton D, Reicin A et al (2004). Preliminary Cardiovascular Safety Data from the APPROVe Study, Presented at the annual meeting of the American College of Rheumatology, San Antonio, Texas, October 18. Abstract available at: http://www.rheumatology.org/annual/press/APPROVesession_annouce.asp .
- Sainati S, Ingram D, Talwalker S, Geiss G (2000). Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of the progression of Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, 180 [Abstract].
- Schmidt M (1996). Rey Auditory Verbal Learning Test. A Handbook. Western Psychological Services: Los Angeles.
Cited by
Sorted by citations
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“, 2008), and selective COX-2 inhibitors (Aisen et al., 2003; Thal et al., 2005) failed to show any”
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 2,075
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
“(Continued) Observation period Study period (years, mean) Setting MCI definition Outcome Randomized trial settings Thal et al. (2005) (36) 4 RCT in specialist centres Criteria: patient reports memory problem, or informant reports that patient has memory problem; informant reports that patient s…”
BackgroundInfluentialLautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., & Almeida, O. P. (2008) · JAMA · doi:10.1001/jama.300.9.1027 · Cited by 1,637
Mild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Petersen, R. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp0910237 · Cited by 1,289
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
“If nothing else, would it not be prudent to know what effect the drugs are having on cognition in this very large population, especially in view of reports that NSAIDs might actually increase AD risk under certain conditions (Thal et al. 2005; Breitner et al. 2009)? Moreover, even if all the positive results from the…”
BackgroundResultPetersen, R. C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000313 · Cited by 1,082
Mild Cognitive Impairment: An Overview
Petersen, R. C., & Negash, S. (2008) · CNS Spectrums · doi:10.1017/s1092852900016151 · Cited by 692
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
“Despite these multiple mechanisms, recent clinical trials with selective COX-2 inhibitors and the mixed COX-1/ COX-2 inhibitor naproxen have been uniformly disappointing (Aisen et al., 2003; Reines et al., 2004; Thal et al., 2005).”
BackgroundCastellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 596
2009 Alzheimer's disease facts and figures
Alzheimer's Association (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.03.001 · Cited by 555
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538
“Pharmacological treatments, such as AChE inhibitors and memantine, have been shown to reduce or delay MCI to AD conversion [83-87].”
BackgroundTau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
“Unexpectedly, clinical trials targeting inflammation with NSAIDs have not improved cognition in AD patients [111, 112].”
BackgroundDeciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib
Ross, J. S., Hill, K., Egilman, D. S., & Krumholz, H. M. (2008) · JAMA · doi:10.1001/jama.299.15.1800 · Cited by 466
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“Despite these multiple mechanisms, recent clinical trials with selective COX-2 inhibitors and the mixed COX-1/ COX-2 inhibitor naproxen have been uniformly disap- pointing (Reines et al. 2004; Thal et al. 2005).”
BackgroundInflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
“Another study with rofecoxib, conducted in patients with mild cognitive impairment (MCI), suggested a deleterious effect of rofecoxib (Thal et al., 2005).”
BackgroundKueper, J. K., Speechley, M. R., & Montero‐Odasso, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170991 · Cited by 461
Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice
Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., Manalastas, A., Hilfiker, M., Pfister, S., Schwerdel, C., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-151 · Cited by 400
Inflammation and Alzheimer's disease: Possible role of periodontal diseases
Kamer, A. R., Craig, R. G., Dasanayake, A. P., Bryś, M., Głodzik-Sobańska, L., & de Leon, M. J. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.08.004 · Cited by 419
Choi, S., Aïd, S., & Bosetti, F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.01.002 · Cited by 408
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
“Thus a large trial of rofecoxib found an increased risk of conversion to AD in the MCI-treated group (Thal et al., 2005).”
BackgroundNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351
Amyloid imaging in mild cognitive impairment subtypes
Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., López, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 349
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 331
Extended results of the Alzheimer's disease anti‐inflammatory prevention trial
Breitner, J. C. S., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. A., Green, R. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.014 · Cited by 327
“Even in patients with milder cognitive symptoms, incidence of AD was found to increase in those who received the cyclooxygenase-2(COX-2)-selective NSAID rofecoxib [12].”
BackgroundInflammaging as a prodrome to Alzheimer's disease
Giunta, B., Fernandez, F., Nikolic, W. V., Obregon, D., Rrapo, E., Town, T., & Tan, J. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-51 · Cited by 327
“After preliminary studies produced encouraging results with nonsteroidal antiinflammatory drugs (NSAIDs) for AD treatment, [155,156] a series of larger studies were launched that tested glucocorticoid therapy, [157] NSAIDs, [158-160] and hydroxychloroquine [161] on patients with AD and MCI and also cognitively normal…”
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 335
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients
Rao, J. S., Keleshian, V. L., Klein, S. L., & Рапопорт, С. И. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.55 · Cited by 305
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 311
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Cognitive intervention for persons with mild cognitive impairment: A meta-analysis
Li, H., Li, J., Li, N., Li, B., Wang, P., & Zhou, T. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.11.003 · Cited by 297
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
“…group Shumaker et al (2003)24 WHIMS study, oestrogen + progesterone group Viswanathan et al (2009)25 VISP study Ball et al (2002)26 ACTIVE study Thal et al (2005)27 Rofecoxib protocol 078 Petersen et al (2005)28‡ ADCS Donepezil and Vitamin E trial Feldman et al (2007)29 InDDEx study Oken et…”
BackgroundLyketsos, C. G., Colenda, C. C., Beck, C. M., Blank, K., Doraiswamy, M. P., Kalunian, D. A., & Yaffe, K. S. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221334.65330.55 · Cited by 274
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B. G., Gauthier, S. G., Scinto, L. F. M., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 269
“Male 238 (48) 223 (45) 239 (45) 216 (41)”
Targeting neuroinflammation in Alzheimer’s disease
Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86958 · Cited by 261
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E., Boza‐Serrano, A., Brioschi, S., Castro‐Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 241
Treatment for mild cognitive impairment: systematic review
Cooper, C., Li, R., Lyketsos, C. G., & Livingston, G. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127811 · Cited by 229
Chen, J.-H., Lin, K.-P., & Chen, Y.-C. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60402-2 · Cited by 288
Effective Pharmacologic Management of Alzheimer’s Disease
Farlow, M. R., & Cummings, J. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.036 · Cited by 227
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Donepezil treatment of patients with MCI
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R. S., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 212
Self-citationNSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Grill, J. D., & Karlawish, J. H. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt58 · Cited by 203
Townsend, K. P., & Praticò, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3620rev · Cited by 194
“…both 9 S. A. Reines et al., 2004 RCT Rofecoxib No significant effect 10 J. Couzin et al., 2004 RCT Celecoxib naproxen Started on 01/2001 and suspended in 12/2004 81 L. J. Thal et al., 2005 RCT (MCI) Rofecoxib No significant effect 80 RCT: randomized controlled trial; MCI: mild cognitive impairment.”
BackgroundDONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 194
Antirheumatic drug use and the risk of acute myocardial infarction
Suissa, S., Bernatsky, S., & Hudson, M. (2006) · Arthritis Care & Research · doi:10.1002/art.22094 · Cited by 192
Fink, H. A., Jutkowitz, E., McCarten, J. R., Hemmy, L. S., Butler, M., Davila, H. W., Ratner, E. R., Calvert, C., Barclay, T. R., Brasure, M., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1529 · Cited by 205
Levey, A. I., Lah, J. J., Goldstein, F. C., Steenland, K., & Bliwise, D. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.006 · Cited by 187
Latta, C. H., Brothers, H. M., & Wilcock, D. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.061 · Cited by 188
“…aspirin (Group et al., 2008), the anti-malarial and anti-inflammatory hydroxychloroquine (Van Gool et al., 2001), the corticosteroid prednisone (Aisen et al., 2000) and the NSAIDs rofecoxib, naproxen, and diclofenac (Scharf et al., 1999, Aisen et al., 2003, Reines et al., 2004, Thal et al., 2005).”
BackgroundRisk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Breitner, J. C. S., Haneuse, S., Walker, R. L., Dublin, S., Crane, P. K., Gray, S. L., & Larson, E. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a18691 · Cited by 175
Cognitive dysfunction with aging and the role of inflammation
Simen, A. A., Bordner, K. A., Martin, M. P., Moy, L. A., & Barry, L. C. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311399145 · Cited by 186
“Trials of rofecoxib [Thal et al. 2005], triflusal [Gomez-Isla et al. 2008], and celecoxib [Small et al. 2008] in patients with MCI were inconsistent.”
BackgroundNeuroinflammation and Memory: The Role of Prostaglandins
Hein, A. M., & O’Banion, M. K. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8066-z · Cited by 176
Feldman, H., & Jacova, C. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.8.645 · Cited by 179
Current approaches in the treatment of Alzheimer's disease
Shah, R. S., Lee, H., Zhu, X., Perry, G. L., Smith, M. A., & Castellani, R. J. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.005 · Cited by 178
Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment
Psaty, B. M., & Kronmal, R. A. (2008) · JAMA · doi:10.1001/jama.299.15.1813 · Cited by 175
Report of the task force on designing clinical trials in early (predementia) AD
Aisen, P. S. S., Andrieu, S., Sampaio, C., Carrillo, M. C., Khachaturian, Z. S., Dubois, B., Feldman, H., Petersen, R. C., Siemers, E., Doody, R. S., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e318207b1b9 · Cited by 173
Imaging Microglial Activation During Neuroinflammation and Alzheimer’s Disease
Venneti, S., Wiley, C. A., & Kofler, J. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9142-2 · Cited by 172
“…or treatment trials with selective or non-selective cyclo-oxygenase inhibitors have been disappointing so far (Aisen et al. 2003; Thal et al. 2005; Group et al. 2007), suggesting that the beneficial effects of NSAIDs are not due to their anti-inflammatory actions (Heneka and…”
BackgroundMild Cognitive Impairment in Geriatrics
Tangalos, E. G., & Petersen, R. C. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.06.005 · Cited by 182
Mental health and periodontal and peri‐implant diseases
Ball, J., & Darby, I. B. (2022) · Periodontology 2000 · doi:10.1111/prd.12452 · Cited by 187
Disease‐modifying therapies in Alzheimer's disease
Salloway, S., Mintzer, J. E., Weiner, M., & Cummings, J. L. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.10.001 · Cited by 163
Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease
Hanzel, C. E., Binette, A. P., Pimentel, L. S. B., Iulita, M. F., Allard, S. T. M., Ducatenzeiler, A., Carmo, S. D., & Cuello, A. C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.026 · Cited by 164
“…trials applying NSAIDs to clinically diagnosed AD cases have failed to slow down disease progression, suggesting that preventing inflammation at the clinical, more advanced stages is less likely to result in a beneficial outcome (Aisen et al., 2003; Martin et al., 2008; Thal et al., 2005).”
BackgroundADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312383 · Cited by 160
Choi, S., Langenbach, R. I., & Bosetti, F. (2007) · The FASEB Journal · doi:10.1096/fj.07-9411com · Cited by 159
Cai, M., Lee, J., & Yang, E. J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1665-3 · Cited by 163
Clinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158
“…not treatment but secondary Reines et al. (2004) AD 692 Rofecoxib 25 mg 1 year Cognitive change (ADAS-Cog) No difference between treatment groups Thal et al. (2005) MCI 725 Rofecoxib 25 mg Up to 4 years Cognitive change (ADAS-Cog) Conversion to dementia diagnosis No difference between treatment…”
MethodKidd, P. M. (2008) · PubMed · Cited by 158
Clinical trials in mild cognitive impairment: lessons for the future
Jelić, V. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072926 · Cited by 156
(2011) · Routledge eBooks · doi:10.4324/9780203152836-7 · Cited by 154
Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review
Stephan, B. C. M., Minett, T., Pagett, E., Siervo, M., Brayne, C., & McKeith, I. G. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001909 · Cited by 154
Aïd, S., Langenbach, R. I., & Bosetti, F. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-17 · Cited by 151
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease
Ferretti, M. T., Bruno, M. A., Ducatenzeiler, A., Klein, W. L., & Cuello, A. C. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.007 · Cited by 151
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
AD Collaborative Group (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70293-4 · Cited by 149
Endpoints for trials in Alzheimer's disease: a European task force consensus
Vellas, B. J., Andrieu, S., Sampaio, C., Coley, N., & Wilcock, G. K. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70087-5 · Cited by 152
Chertkow, H. M., Massoud, F., Nasreddine, Z. S., Belleville, S., Joanette, Y., Bocti, C., Drolet, V., Kirk, J., Freedman, M., & Bergman, H. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070797 · Cited by 147
“CMAJ • May 6, 2008 • 178(10)1282 Table 3: Classes of drugs that have shown no benefit* on primary outcome measures for the prevention of progression to dementia in patients with mild cognitive impairment Drug class Study No. of patients Outcome Quality of study† Comments Cholinesterase inhibitors Donepezil Salloway et…”
BackgroundLong-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H. S., West, C. R., Robbins, J. L., & Niculescu, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 144
[Alzheimer's disease Neuroimaging Initiative (ADNI)].
Iwatsubo, T. (2011) · PubMed · Cited by 141
Tai Chi Chuan and Baduanjin Increase Grey Matter Volume in Older Adults: A Brain Imaging Study
Tao, J., Liu, J., Liu, W., Huang, J., Xue, X., Chen, X., Wu, J., Zheng, G., Chen, B., Li, M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170477 · Cited by 143
Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1970 · Cited by 138
Neuroinflammation and fractalkine signaling in Alzheimer’s disease
Finneran, D. J., & Nash, K. R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1412-9 · Cited by 132
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
Mishra, A., Bandopadhyay, R., Singh, P. K., Mishra, P. S., Sharma, N., & Khurana, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00806-4 · Cited by 134
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
Palmer, A. M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.007 · Cited by 136
Metadata
- Authors
- on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., Baranak, C. C., & Reines, S. A.
- Affiliations
- University of California San Diego (US)
- New York University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lines, Christopher R
- ORCID
- Ferris, Steven H
- Venue
- Neuropsychopharmacology
- Published
- 2005-03-02
- Volume
- 30
- Issue
- 6
- Pages
- 1204-1215
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2051776695
- Cited by
- 402
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 6 · 2023: 15 · 2022: 16 · 2021: 16 · 2020: 6 · 2019: 12 · 2018: 14 · 2017: 19 · 2016: 15 · 2015: 20 · 2014: 13 · 2013: 14 · 2012: 24
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Rochester
- Dartmouth College
- Towson University
- York University
- University of Illinois at Urbana-Champaign
- School of Medicine, New York University
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- rofecoxib, mild cognitive impairment, Alzheimer's disease, COX-2 inhibitors, COX-2 inhibition, disease progression, anti-inflammatory therapy
- MeSH terms
- Aged, Cognition Disorders, Dementia, Double-Blind Method, Female, Humans, Lactones, Male, Membrane Proteins, Neuropsychological Tests, Prostaglandin-Endoperoxide Synthases, Psychiatric Status Rating Scales, Sulfones, Cyclooxygenase Inhibitors, Disease Progression, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
